Clinical Trial

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-12-28; most recent amendment 2026-05-15.
Status change: Not Yet Recruiting → Recruiting 2026-03-05
Trial Details
NCT Number NCT07331155
Lead Sponsor Nanjing Leads Biolabs Co.,Ltd
Collaborators: Peking University Cancer Hospital & Institute
Conditions Advanced Solid Tumour
Enrollment 110 participants
Start Date 2026-02-26
Primary Completion 2028-12-26 (estimated)
Study Completion 2028-12-26 (estimated)
Updated on ClinicalTrials.gov 2026-05-18